XTX Topco Ltd Acquires Shares of 5,048 Enovis Co. (NYSE:ENOV)

XTX Topco Ltd bought a new position in shares of Enovis Co. (NYSE:ENOV) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,048 shares of the company’s stock, valued at approximately $217,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ridgewood Investments LLC acquired a new position in Enovis during the 2nd quarter worth about $44,000. DekaBank Deutsche Girozentrale bought a new position in shares of Enovis in the third quarter worth about $55,000. Innealta Capital LLC acquired a new position in shares of Enovis during the second quarter worth approximately $65,000. Benjamin F. Edwards & Company Inc. grew its stake in shares of Enovis by 28.1% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,691 shares of the company’s stock valued at $76,000 after purchasing an additional 371 shares during the last quarter. Finally, FMR LLC increased its holdings in shares of Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after purchasing an additional 484 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Stock Down 1.8 %

NYSE:ENOV opened at $42.49 on Friday. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. Enovis Co. has a 12-month low of $38.27 and a 12-month high of $65.03. The stock’s fifty day simple moving average is $44.68 and its 200-day simple moving average is $44.50. The firm has a market capitalization of $2.37 billion, a P/E ratio of -19.40 and a beta of 1.94.

Enovis (NYSE:ENOV) last posted its earnings results on Wednesday, November 6th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.11. The company had revenue of $505.22 million during the quarter, compared to analyst estimates of $504.44 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company’s revenue for the quarter was up 21.0% compared to the same quarter last year. During the same period in the previous year, the company earned $0.56 EPS. Equities research analysts expect that Enovis Co. will post 2.79 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. JMP Securities initiated coverage on Enovis in a report on Thursday, October 3rd. They set an “outperform” rating and a $62.00 price objective on the stock. Evercore ISI cut their price target on Enovis from $62.00 to $58.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 1st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $65.00 price target on shares of Enovis in a report on Thursday, November 7th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $67.00.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.